Non-pharmacological modulation of the autonomic tone to treat heart failure.

The autonomic nervous system has a significant role in the pathophysiology and progression of heart failure. The absence of any recent breakthrough advances in the medical therapy of heart failure has led to the evolution of innovative non-pharmacological interventions that can favourably modulate the cardiac autonomic tone. Several new therapeutic modalities that may act at different levels of the autonomic nervous system are being investigated for their role in the treatment of heart failure. The current review examines the role of renal denervation, vagal nerve stimulators, carotid baroreceptors, and spinal cord stimulators in the treatment of heart failure.

[1]  M. Böhm,et al.  Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. , 2013, International journal of cardiology.

[2]  H. Krum,et al.  Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension , 2013, Circulation.

[3]  B. Williams,et al.  Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. , 2013, European heart journal.

[4]  H. Krum,et al.  Substantial Reduction in Single Sympathetic Nerve Firing After Renal Denervation in Patients With Resistant Hypertension , 2013, Hypertension.

[5]  A. Hughes,et al.  First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. , 2013, International journal of cardiology.

[6]  Mark D. Huffman,et al.  Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.

[7]  Luigi Tavazzi,et al.  Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI‐HF trial , 2012, European journal of heart failure.

[8]  Y. Ozaki.  European Society of Cardiology (ESC) Congress Report from Munich 2012. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[9]  S. Mittal,et al.  A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. , 2012, Journal of the American College of Cardiology.

[10]  D. V. Van Wagoner,et al.  Effects of Percutaneous Stimulation of Both Sympathetic and Parasympathetic Cardiac Autonomic Nerves on Cardiac Function in Dogs , 2012, Innovations.

[11]  U. Schotten,et al.  Renal Sympathetic Denervation Suppresses Postapneic Blood Pressure Rises and Atrial Fibrillation in a Model for Sleep Apnea , 2012, Hypertension.

[12]  James Winter,et al.  Mechanisms underlying the autonomic modulation of ventricular fibrillation initiation—tentative prophylactic properties of vagus nerve stimulation on malignant arrhythmias in heart failure , 2012, Heart Failure Reviews.

[13]  Martin Borggrefe,et al.  Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. , 2012, American heart journal.

[14]  Gianfranco Parati,et al.  The human sympathetic nervous system: its relevance in hypertension and heart failure. , 2012, European heart journal.

[15]  M. Zile,et al.  Effects of autonomic modulation: more than just blood pressure. , 2012, Journal of the American College of Cardiology.

[16]  M. Böhm,et al.  Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. , 2012, Journal of the American College of Cardiology.

[17]  G. Bakris,et al.  Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. , 2012, Journal of the American Society of Hypertension : JASH.

[18]  P. Gargiulo,et al.  Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: a clinical appraisal , 2011, Heart.

[19]  G. Bakris,et al.  Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. , 2011, Journal of the American College of Cardiology.

[20]  H. Krum,et al.  Sympatho-renal axis in chronic disease , 2011, Clinical Research in Cardiology.

[21]  Jason Ng,et al.  Autonomic Remodeling in the Left Atrium and Pulmonary Veins in Heart Failure: Creation of a Dynamic Substrate for Atrial Fibrillation , 2011, Circulation. Arrhythmia and electrophysiology.

[22]  H. Krum,et al.  Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Study , 2011, Circulation.

[23]  J. Goldberg,et al.  Recruitment and blocking properties of the CardioFit stimulation lead , 2011, Journal of neural engineering.

[24]  Symplicity Htn Investigators,et al.  Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: Durability of Blood Pressure Reduction Out to 24 Months , 2011, Hypertension.

[25]  Markus Zabel,et al.  Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. , 2011, European heart journal.

[26]  H. Yin,et al.  Inhibition of Cardiac Ca2+ Release Channels (RyR2) Determines Efficacy of Class I Antiarrhythmic Drugs in Catecholaminergic Polymorphic Ventricular Tachycardia , 2011, Circulation. Arrhythmia and electrophysiology.

[27]  M. Zile,et al.  Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. , 2011, Journal of cardiac failure.

[28]  A. Milby,et al.  Vagus nerve stimulation for epilepsy and depression , 2011, Neurotherapeutics.

[29]  M. Böhm,et al.  Renal sympathetic denervation for treatment of electrical storm: first-in-man experience , 2011, Clinical Research in Cardiology.

[30]  H. Yin,et al.  Catecholaminergic Polymorphic Ventricular Tachycardia Release Channels ( RyR 2 ) Determines Efficacy of Class I 2 + Inhibition of Cardiac Ca , 2011 .

[31]  Peter J. Schwartz,et al.  Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions , 2011, Heart Failure Reviews.

[32]  Hani N. Sabbah,et al.  Vagus nerve stimulation in experimental heart failure , 2011, Heart Failure Reviews.

[33]  B. Olshansky,et al.  Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation , 2011, Heart Failure Reviews.

[34]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[35]  Jagmeet P. Singh,et al.  Implantable sensors for heart failure. , 2010, Circulation. Arrhythmia and electrophysiology.

[36]  Jens Jordan,et al.  Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. , 2010, Journal of the American College of Cardiology.

[37]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[38]  Sana M. Al-Khatib,et al.  Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study. , 2010, Journal of the American College of Cardiology.

[39]  Jens Jordan,et al.  Carotid Baroreceptor Stimulation, Sympathetic Activity, Baroreflex Function, and Blood Pressure in Hypertensive Patients , 2010, Hypertension.

[40]  Yen-Hung Lin,et al.  The relationship between aminoterminal propeptide of type III procollagen and heart rate variability parameters in heart failure patients: a potential serum marker to evaluate cardiac autonomic control and sudden cardiac death , 2010, Clinical chemistry and laboratory medicine.

[41]  H. Krum,et al.  Renal sympathetic-nerve ablation for uncontrolled hypertension. , 2009, The New England journal of medicine.

[42]  Jagmeet P. Singh,et al.  Device diagnostics and long-term clinical outcome in patients receiving cardiac resynchronization therapy. , 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[43]  Javed Butler,et al.  The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. , 2009, Journal of the American College of Cardiology.

[44]  Zoran B. Popović,et al.  Chronic Vagus Nerve Stimulation Improves Autonomic Control and Attenuates Systemic Inflammation and Heart Failure Progression in a Canine High-Rate Pacing Model , 2009, Circulation. Heart failure.

[45]  P. Schauerte,et al.  Atrioventricular (AV) node vagal stimulation by transvenous permanent lead implantation to modulate AV node function: safety and feasibility in humans. , 2009, Heart rhythm.

[46]  J. Floras,et al.  Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. , 2009, Journal of the American College of Cardiology.

[47]  D. Zipes,et al.  Spinal Cord Stimulation Improves Ventricular Function and Reduces Ventricular Arrhythmias in a Canine Postinfarction Heart Failure Model , 2009, Circulation.

[48]  J. Greenwood,et al.  Gender differences in sympathetic neural activation following uncomplicated acute myocardial infarction. , 2009, European heart journal.

[49]  J. Floras,et al.  Muscle sympathetic nerve activity in women and men following acute myocardial infarction: a meaningful difference? , 2009, European heart journal.

[50]  Krzysztof Bartus,et al.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2009, The Lancet.

[51]  E. Piotrowicz,et al.  Variable Effects of Physical Training of Heart Rate Variability, Heart Rate Recovery, and Heart Rate Turbulence in Chronic Heart Failure , 2009, Pacing and clinical electrophysiology : PACE.

[52]  Luigi Tavazzi,et al.  Long term vagal stimulation in patients with advanced heart failure First experience in man , 2008, European journal of heart failure.

[53]  Brian Olshansky,et al.  Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. , 2008, Circulation.

[54]  Delon Wu,et al.  Intracellular calcium dynamics and acetylcholine-induced triggered activity in the pulmonary veins of dogs with pacing-induced heart failure. , 2008, Heart rhythm.

[55]  E. Irwin,et al.  Chronic Baroreceptor Activation Enhances Survival in Dogs With Pacing-Induced Heart Failure , 2007, Hypertension.

[56]  M. Esler,et al.  Differing Pattern of Sympathoexcitation in Normal-Weight and Obesity-Related Hypertension , 2007, Hypertension.

[57]  Masahiro Ogawa,et al.  Left stellate ganglion and vagal nerve activity and cardiac arrhythmias in ambulatory dogs with pacing-induced congestive heart failure. , 2007, Journal of the American College of Cardiology.

[58]  M. Malik,et al.  Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study , 2006, The Lancet.

[59]  M. L. La Rovere,et al.  Cardiac resynchronization therapy improves heart rate profile and heart rate variability of patients with moderate to severe heart failure. , 2005, Journal of the American College of Cardiology.

[60]  Mustafa M. Husain,et al.  Vagus Nerve Stimulation for Treatment-Resistant Depression: A Randomized, Controlled Acute Phase Trial , 2005, Biological Psychiatry.

[61]  K. Muramoto,et al.  Efferent Vagal Nerve Stimulation Protects Heart Against Ischemia-Induced Arrhythmias by Preserving Connexin43 Protein , 2005, Circulation.

[62]  D. Zipes,et al.  Thoracic Spinal Cord Stimulation Reduces the Risk of Ischemic Ventricular Arrhythmias in a Postinfarction Heart Failure Canine Model , 2005, Circulation.

[63]  Douglas L Mann,et al.  Mechanisms and models in heart failure: the biomechanical model and beyond. , 2005, Circulation.

[64]  M. Schwaiger,et al.  Assessment of cardiac sympathetic neuronal function using PET imaging , 2004, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[65]  J. Armour,et al.  Cardiac neuronal hierarchy in health and disease. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[66]  S. Goldsmith.  Interactions between the sympathetic nervous system and the RAAS in heart failure , 2004, Current heart failure reports.

[67]  Masaru Sugimachi,et al.  Vagal Nerve Stimulation Markedly Improves Long-Term Survival After Chronic Heart Failure in Rats , 2003, Circulation.

[68]  M. Pfeffer,et al.  Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON) , 2003, European journal of heart failure.

[69]  C. Heck,et al.  Vagus nerve stimulation therapy, epilepsy, and device parameters: Scientific basis and recommendations for use , 2002, Neurology.

[70]  J. Olgin,et al.  Effects of Thoracic Spinal Cord Stimulation on Cardiac Autonomic Regulation of the Sinus and Atrioventricular Nodes , 2002, Journal of cardiovascular electrophysiology.

[71]  T. Thrasher.  Unloading arterial baroreceptors causes neurogenic hypertension. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[72]  Pharmacoeconomics news from the 2002 European Society of Cardiology (ESC) Congress , 2002 .

[73]  P. Schauerte,et al.  Catheter Stimulation of Cardiac Parasympathetic Nerves in Humans: A Novel Approach to the Cardiac Autonomic Nervous System , 2001, Circulation.

[74]  J. Floras.  Arterial Baroreceptor and Cardiopulmonary Reflex Control of Sympathetic Outflow in Human Heart Failure , 2001, Annals of the New York Academy of Sciences.

[75]  A J Camm,et al.  Baroreflex Sensitivity and Heart Rate Variability in the Identification of Patients at Risk for Life-Threatening Arrhythmias: Implications for Clinical Trials , 2001, Circulation.

[76]  C. Liang,et al.  Alterations by norepinephrine of cardiac sympathetic nerve terminal function and myocardial beta-adrenergic receptor sensitivity in the ferret: normalization by antioxidant vitamins. , 2000, Circulation.

[77]  N. Kobayashi,et al.  Effects of angiotensin II type 1 receptor antagonist on nitric oxide synthase expression and myocardial remodeling in Goldblatt hypertensive rats. , 2000, Journal of cardiovascular pharmacology.

[78]  H. Kosaka,et al.  Role of nitric oxide in vascular hyper‐responsiveness to norepinephrine in hypertensive Dahl rats , 1998, Journal of hypertension.

[79]  J. Bigger,et al.  Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction , 1998, The Lancet.

[80]  S Cerutti,et al.  Individual recognition by heart rate variability of two different autonomic profiles related to posture. , 1997, Circulation.

[81]  G. Jennings,et al.  Adrenergic nervous system in heart failure. , 1997, The American journal of cardiology.

[82]  I. Kopin,et al.  Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. , 1995, The Journal of clinical endocrinology and metabolism.

[83]  R Maestri,et al.  Physiology and pathophysiology of heart rate and blood pressure variability in humans: is power spectral analysis largely an index of baroreflex gain? , 1995, Clinical science.

[84]  J. Nadeau,et al.  Baroreflex failure in a patient with central nervous system lesions involving the nucleus tractus solitarii. , 1994, Hypertension.

[85]  J. Netterville,et al.  The diagnosis and treatment of baroreflex failure. , 1993, The New England journal of medicine.

[86]  M. Piepoli,et al.  Comparison of different methods for assessing sympathovagal balance in chronic congestive heart failure secondary to coronary artery disease. , 1992, The American journal of cardiology.

[87]  M. Creager.  Baroreceptor reflex function in congestive heart failure. , 1992, The American journal of cardiology.

[88]  S. S. Hull,et al.  Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. , 1991, Circulation research.

[89]  A. Malliani,et al.  Spectral analysis to assess increased sympathetic tone in arterial hypertension. , 1991, Hypertension.

[90]  D. Seals.  Sympathetic neural adjustments to stress in physically trained and untrained humans. , 1991, Hypertension.

[91]  A. Malliani,et al.  Continuous 24-hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects. , 1990, Circulation.

[92]  F. Abboud,et al.  Mechanisms of resetting of arterial baroreceptors: an overview. , 1988, The American journal of the medical sciences.

[93]  H. L. Stone,et al.  Baroreceptor Reflex Control of Heart Rate: A Predictor of Sudden Cardiac Death , 1982, Circulation.

[94]  J. Cohn,et al.  Angiotensin-converting enzyme inhibition in congestive heart failure: the concept. , 1982, American Journal of Cardiology.

[95]  E. W. V. Stee.  Autonomic innervation of the heart. , 1978 .

[96]  E. W. van Stee.  Autonomic innervation of the heart. , 1978, Environmental health perspectives.

[97]  D L Eckberg,et al.  Defective cardiac parasympathetic control in patients with heart disease. , 1971, The New England journal of medicine.

[98]  A. Ljungqvist,et al.  The adrenergic innervation of intrarenal glomerular and extra-glomerular circulatory routes. , 1970, Nephron.

[99]  J. H. Green,et al.  Baroceptor Function in Chronic Renal Hypertension , 1956, Circulation research.